Drugs / Taselisib
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT02390427 | Apr 2015 → Dec 2022 | breast carcinoma, metastatic neoplasm | Otto Metzger, MD | Completed | No outcome recorded |
| Phase 1 | NCT02389842 | Mar 2015 → Oct 2018 | breast cancer | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT01980953 | Nov 2013 → Jul 2014 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01967966 | Nov → Dec 2013 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01862081 | Jul 2013 → Jun 2017 | Her2-receptor negative breast cancer, non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01814709 | Apr → Aug 2013 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01296555 | Mar 2011 → Jun 2021 | non-Hodgkin lymphoma | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03290092 | Jul 2017 → Feb 2019 | PIK3CA-related overgrowth spectrum | Centre Hospitalier Universitaire Dijon | Terminated | No outcome recorded |
| Phase 1/2 | NCT02457910 | Jun 2015 → Dec 2018 | estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer, triple-negative breast carcinoma | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02285179 | Nov 2014 → May 2022 | breast cancer | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04439175 | Feb 2016 → Nov 2020 overdue | adult lymphoma, plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02465060 | Aug 2015 → Dec 2026 expected | breast carcinoma, carcinoma of esophagus, cervical carcinoma, colon carcinoma +17 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02273973 | Nov 2014 → Mar 2017 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02785913 | Nov 2014 → Feb 2017 | squamous cell lung carcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02340221 | Apr 2015 → Jun 2021 | breast cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Taselisib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02465060 ↗ |
| Known as | GDC-0032 | “A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)” NCT02785913 ↗ |
| Known as | RG-7604 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2387080 ↗ |
| Action | Inhibit | “Taselisib is an oral, selective PI3K inhibitor” PMID 31402321 ↗ Aug 2019 |
| Modality | Small molecule | — CHEMBL2387080 ↗ |
| Route | Oral | “GDC-0032 will be administered orally” NCT01296555 ↗ |
| Target | PIK3CA | “blocking PIK3CA” NCT04439175 ↗ |